(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

A setback for GSK after one of its late-stage pipeline assets failed to win the support of a US panel today triggered a 6% ...

Another week where the market has traded in a narrow range comes to an end today. The Nifty, so far, is down 38 points for ...

--In Europe, the Stoxx Europe 600 climbed 0.3% in morning trading. France's CAC 40 increased 0.4% and Germany's DAX rose 0.3%. Vestas Wind Systems added 11.6% after an upgrade. GSK lost over 6.0%, and ...

GSK shares sink after FDA panel rejects Blenrep cancer drug, raising doubts over turnaround strategy. GSK (LSE: GSK) investors took a sharp knock on Friday after its much-hyped blood cancer drug, ...

Euro US Dollar, US Dollar Japanese Yen, US Dollar Index Futures, United States 10-Year. Read 's Market Analysis on Investing.com UK.